Setting

Asia Pacific Pharmaceutical Manufacturing Industry 2020-2027 by Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country: Trend Forecast and Growth Opportunity

Published: 30 Mar 2021 | Report Code: 10247953 | Pages: 130

Asia Pacific pharmaceutical manufacturing industry will grow by 14.8% annually with a total addressable market cap of $1,034.6 billion over 2021-2027 driven by increased drug approvals, increasing prevalence of chronic ailments, growing geriatric population, high investment in research and development, and increasing per capita healthcare expenditure amid the COVID-19 pandemic. Highlighted with 33 tables and 63 figures, this 130-page report “Asia Pacific Pharmaceutical Manufacturing Industry 2020-2027 by Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific pharmaceutical manufacturing industry and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate/forecast from 2020 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Industry Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Industry Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific industry is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific pharmaceutical manufacturing industry in every aspect of the classification from perspectives of Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country. Based on Formulation, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • Tablets • Capsules • Injectable • Sprays • Suspensions • Powders • Other Formulations Based on Route of Administration, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • Oral Medicine • Topical Medicine • Parenteral Medicine • Inhalations • Other Routes of Administration Based on Age Group, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • Children & Adolescents • Adults • Geriatric Based on Therapeutic Application, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • Cardiovascular Diseases • Pain • Diabetes • Cancer • Respiratory Diseases • Neurological Diseases • Orthopedics • Other Applications Based on Drug Type, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • Branded Prescription Drugs • Generic Prescription Drugs • OTC Drugs Based on Distribution Channels, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • Retail Channels • Non-retail Channels Based on Manufacturing Facility, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • In-house Facility • Outsourced Facility Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) For each key country, detailed analysis and data for annual production value are available for 2017-2027. The breakdown of key national industry by Formulation, Route of Administration, and Drug Type over the forecast years is also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including industry leaders and important emerging players. Specifically, potential risks associated with investing in Asia Pacific pharmaceutical manufacturing industry are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Abbott Laboratories Aenova Group Amgen AstraZeneca Catalent Inc. Eli Lilly and Company F. Hoffmann-La Roche Ltd. Gilead Sciences GlaxoSmithKline plc Johnson & Johnson Lonza Group Lupin Merck & Co., Inc. Novartis AG Novo Nordisk Pfizer, Inc. Roche Sanofi SA Takeda (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) 

Table Of Contents

1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Industry Research Methodology 11
1.2.2 Industry Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 14
1.2.6 Industry Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 Industry Overview and Dynamics 20
2.1 Industry Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the Industry 24
2.2 Major Growth Drivers 26
2.3 Industry Restraints and Challenges 29
2.4 Emerging Opportunities and Industry Trends 32
2.5 Porter’s Fiver Forces Analysis 36
3 Segmentation of Asia Pacific Industry by Formulation 40
3.1 Industry Overview by Formulation 40
3.2 Tablets 42
3.3 Capsules 43
3.4 Injectable 44
3.5 Sprays 45
3.6 Suspensions 46
3.7 Powders 47
3.8 Other Formulations 48
4 Segmentation of Asia Pacific Industry by Route of Administration 49
4.1 Industry Overview by Route of Administration 49
4.2 Oral Medicine 51
4.3 Topical Medicine 52
4.4 Parenteral Medicine 53
4.5 Inhalations 54
4.6 Other Routes of Administration 55
5 Segmentation of Asia Pacific Industry by Age Group 56
5.1 Industry Overview by Age Group 56
5.2 Children & Adolescents 58
5.3 Adults 59
5.4 Geriatric 60
6 Segmentation of Asia Pacific Industry by Therapeutic Application 61
6.1 Industry Overview by Therapeutic Application 61
6.2 Cardiovascular Diseases 63
6.3 Pain 64
6.4 Diabetes 65
6.5 Cancer 66
6.6 Respiratory Diseases 67
6.7 Neurological Diseases 68
6.8 Orthopedics 69
6.9 Other Applications 70
7 Segmentation of Asia Pacific Industry by Drug Type 71
7.1 Industry Overview by Drug Type 71
7.2 Branded Prescription Drugs 73
7.3 Generic Prescription Drugs 74
7.4 OTC Drugs 75
8 Segmentation of Asia Pacific Industry by Distribution Channels 76
8.1 Industry Overview by Distribution Channels 76
8.2 Retail Channels 78
8.3 Non-retail Channels 79
9 Segmentation of Asia Pacific Industry by Manufacturing Facility 80
9.1 Industry Overview by Manufacturing Facility 80
9.2 In-house Facility 82
9.3 Outsourced Facility 83
10 Asia-Pacific Industry 2020-2027 by Country 84
10.1 Overview of Asia-Pacific Industry 84
10.2 China 87
10.3 Japan 89
10.4 India 92
10.5 Australia 94
10.6 South Korea 96
10.7 Rest of APAC Region 98
11 Competitive Landscape 100
11.1 Overview of Key Vendors 100
11.2 New Product Launch, Partnership, Investment, and M&A 103
11.3 Company Profiles 104
Abbott Laboratories 104
Aenova Group 106
Amgen 107
AstraZeneca 108
Catalent Inc. 109
Eli Lilly and Company 110
F. Hoffmann-La Roche Ltd. 111
Gilead Sciences 112
GlaxoSmithKline plc 113
Johnson & Johnson 114
Lonza Group 115
Lupin 116
Merck & Co., Inc. 117
Novartis AG 118
Novo Nordisk 119
Pfizer, Inc. 120
Roche 121
Sanofi SA 122
Takeda 123
12 Investing in Asia Pacific Industry: Risk Assessment and Management 124
12.1 Risk Evaluation of Asia Pacific Industry 124
12.2 Critical Success Factors (CSFs) 127
Related Reports and Products 130

List Of Tables

Table 1.  Snapshot of Asia Pacific Pharmaceutical Manufacturing Industry in Balanced Perspective, 2020-2027 18
Table 2. Growth Rate of World Real GDP, 2017-2021 22
Table 3.  Main Product Trends and Industry Opportunities in Asia Pacific Pharmaceutical Manufacturing Industry 32
Table 4. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 40
Table 5. Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 49
Table 6. Asia Pacific Pharmaceutical Manufacturing Industry by Age Group, 2017-2027, $ bn 56
Table 7. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application, 2017-2027, $ bn 61
Table 8. Asia Pacific Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 71
Table 9. Asia Pacific Pharmaceutical Manufacturing Industry by Distribution Channels, 2017-2027, $ bn 76
Table 10. Asia Pacific Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2017-2027, $ bn 80
Table 11. APAC Pharmaceutical Manufacturing Industry by Country, 2017-2027, $ bn 85
Table 12. China Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 88
Table 13. China Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 88
Table 14. China Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 88
Table 15. Japan Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 91
Table 16. Japan Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 91
Table 17. Japan Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 91
Table 18. India Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 93
Table 19. India Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 93
Table 20. India Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 93
Table 21. Australia Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 95
Table 22. Australia Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 95
Table 23. Australia Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 95
Table 24. South Korea Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 97
Table 25. South Korea Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 97
Table 26. South Korea Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 97
Table 27. Pharmaceutical Manufacturing Industry in Rest of APAC by Country/Region, 2017-2027, $ bn 99
Table 28. Abbott Laboratories: Company Snapshot 104
Table 29. Abbott Laboratories: Business Segmentation 104
Table 30. Abbott Laboratories: Product Portfolio 105
Table 31. Abbott Laboratories: Revenue, 2017-2019, $ bn 105
Table 32.  Risk Evaluation for Investing in Asia Pacific Industry, 2020-2027 125
Table 33. Critical Success Factors and Key Takeaways 128



List Of Figures

Figure 1. Research Method Flow Chart 11
Figure 2. Breakdown of Primary Research 13
Figure 3. Bottom-up Approach and Top-down Approach for Industry Estimation 15
Figure 4. Asia Pacific Industry Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027 17
Figure 5. Asia Pacific Pharmaceutical Manufacturing Industry, 2017-2027, $ bn 20
Figure 6. Impact of COVID-19 on Business 24
Figure 7. Primary Drivers and Impact Factors of Asia Pacific Pharmaceutical Manufacturing Industry 26
Figure 8. Primary Restraints and Impact Factors of Asia Pacific Pharmaceutical Manufacturing Industry 29
Figure 9. Investment Opportunity Analysis 33
Figure 10. Porter’s Fiver Forces Analysis of Asia Pacific Pharmaceutical Manufacturing Industry 36
Figure 11. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Formulation, 2020-2027, % of Revenue 41
Figure 12. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Formulation, Value ($ bn) and Share (%) 41
Figure 13. Asia Pacific Pharmaceutical Manufacturing Industry: Tablets, 2017-2027, $ bn 42
Figure 14. Asia Pacific Pharmaceutical Manufacturing Industry: Capsules, 2017-2027, $ bn 43
Figure 15. Asia Pacific Pharmaceutical Manufacturing Industry: Injectable, 2017-2027, $ bn 44
Figure 16. Asia Pacific Pharmaceutical Manufacturing Industry: Sprays, 2017-2027, $ bn 45
Figure 17. Asia Pacific Pharmaceutical Manufacturing Industry: Suspensions, 2017-2027, $ bn 46
Figure 18. Asia Pacific Pharmaceutical Manufacturing Industry: Powders, 2017-2027, $ bn 47
Figure 19. Asia Pacific Pharmaceutical Manufacturing Industry: Other Formulations, 2017-2027, $ bn 48
Figure 20. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration, 2020-2027, % of Revenue 50
Figure 21. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Route of Administration, Value ($ bn) and Share (%) 50
Figure 22. Asia Pacific Pharmaceutical Manufacturing Industry: Oral Medicine, 2017-2027, $ bn 51
Figure 23. Asia Pacific Pharmaceutical Manufacturing Industry: Topical Medicine, 2017-2027, $ bn 52
Figure 24. Asia Pacific Pharmaceutical Manufacturing Industry: Parenteral Medicine, 2017-2027, $ bn 53
Figure 25. Asia Pacific Pharmaceutical Manufacturing Industry: Inhalations, 2017-2027, $ bn 54
Figure 26. Asia Pacific Pharmaceutical Manufacturing Industry: Other Routes of Administration, 2017-2027, $ bn 55
Figure 27. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Age Group, 2020-2027, % of Revenue 56
Figure 28. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Age Group, Value ($ bn) and Share (%) 57
Figure 29. Asia Pacific Pharmaceutical Manufacturing Industry: Children & Adolescents, 2017-2027, $ bn 58
Figure 30. Asia Pacific Pharmaceutical Manufacturing Industry: Adults, 2017-2027, $ bn 59
Figure 31. Asia Pacific Pharmaceutical Manufacturing Industry: Geriatric, 2017-2027, $ bn 60
Figure 32. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application, 2020-2027, % of Revenue 62
Figure 33. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Therapeutic Application, Value ($ bn) and Share (%) 62
Figure 34. Asia Pacific Pharmaceutical Manufacturing Industry: Cardiovascular Diseases, 2017-2027, $ bn 63
Figure 35. Asia Pacific Pharmaceutical Manufacturing Industry: Pain, 2017-2027, $ bn 64
Figure 36. Asia Pacific Pharmaceutical Manufacturing Industry: Diabetes, 2017-2027, $ bn 65
Figure 37. Asia Pacific Pharmaceutical Manufacturing Industry: Cancer, 2017-2027, $ bn 66
Figure 38. Asia Pacific Pharmaceutical Manufacturing Industry: Respiratory Diseases, 2017-2027, $ bn 67
Figure 39. Asia Pacific Pharmaceutical Manufacturing Industry: Neurological Diseases, 2017-2027, $ bn 68
Figure 40. Asia Pacific Pharmaceutical Manufacturing Industry: Orthopedics, 2017-2027, $ bn 69
Figure 41. Asia Pacific Pharmaceutical Manufacturing Industry: Other Applications, 2017-2027, $ bn 70
Figure 42. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Drug Type, 2020-2027, % of Revenue 71
Figure 43. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Drug Type, Value ($ bn) and Share (%) 72
Figure 44. Asia Pacific Pharmaceutical Manufacturing Industry: Branded Prescription Drugs, 2017-2027, $ bn 73
Figure 45. Asia Pacific Pharmaceutical Manufacturing Industry: Generic Prescription Drugs, 2017-2027, $ bn 74
Figure 46. Asia Pacific Pharmaceutical Manufacturing Industry: OTC Drugs, 2017-2027, $ bn 75
Figure 47. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Distribution Channels, 2020-2027, % of Revenue 76
Figure 48. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Distribution Channels, Value ($ bn) and Share (%) 77
Figure 49. Asia Pacific Pharmaceutical Manufacturing Industry: Retail Channels, 2017-2027, $ bn 78
Figure 50. Asia Pacific Pharmaceutical Manufacturing Industry: Non-retail Channels, 2017-2027, $ bn 79
Figure 51. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2020-2027, % of Revenue 81
Figure 52. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Manufacturing Facility, Value ($ bn) and Share (%) 81
Figure 53. Asia Pacific Pharmaceutical Manufacturing Industry: In-house Facility, 2017-2027, $ bn 82
Figure 54. Asia Pacific Pharmaceutical Manufacturing Industry: Outsourced Facility, 2017-2027, $ bn 83
Figure 55. Breakdown of APAC Pharmaceutical Manufacturing Industry by Country, 2020 and 2027, % of Revenue 85
Figure 56. Contribution to APAC 2021-2027 Cumulative Revenue by Country, Value ($ bn) and Share (%) 86
Figure 57.  Pharmaceutical Manufacturing Industry in China, 2017-2027, $ bn 87
Figure 58.  Pharmaceutical Manufacturing Industry in Japan, 2017-2027, $ bn 90
Figure 59.  Pharmaceutical Manufacturing Industry in India, 2017-2027, $ bn 92
Figure 60.  Pharmaceutical Manufacturing Industry in Australia, 2017-2027, $ bn 94
Figure 61.  Pharmaceutical Manufacturing Industry in South Korea, 2017-2027, $ bn 96
Figure 62.  Pharmaceutical Manufacturing Industry in Rest of APAC, 2017-2027, $ bn 98
Figure 63. Growth Stage of Asia Pacific Industrial Robot Software Industry over the Forecast Period 100


?

Key Players (this may not be a complete list and extra companies can be added upon request): 
Abbott Laboratories
Aenova Group
Amgen
AstraZeneca
Catalent Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences
GlaxoSmithKline plc
Johnson & Johnson
Lonza Group
Lupin
Merck & Co., Inc.
Novartis AG
Novo Nordisk
Pfizer, Inc.
Roche
Sanofi SA
Takeda